BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) may result from delayed establishment of corticolimbic circuitry or perturbed dopamine (DA) neurotransmission. Despite the widespread use of stimulants to treat ADHD, little is known regarding their long-term effects on neurotransmitter levels and metabolism. Cyclin-dependent kinase 5 (Cdk5) regulates DA signaling through control of synthesis, postsynaptic responses, and vesicle release. Mice lacking the Cdk5-activating cofactor p35 are deficient in cortical lamination, suggesting altered motor/reward circuitry. METHODS: We employed mice lacking p35 to study the effect of altered circuitry in vivo. Positron emission tomography measured glucose metabolism in the cerebral cortex using 2-deoxy-2-[¹⁸F] fluoro-d-glucose as the radiotracer. Retrograde dye tracing and tyrosine hydroxylase immunostains assessed the effect of p35 knockout on the medial prefrontal cortex (PFC), especially in relation to mesolimbic circuit formation. We defined the influence of Cdk5/p35 activity on catecholaminergic neurotransmission and motor activity via examination of locomotor responses to psychostimulants, monoamine neurotransmitter levels, and DA signal transduction. RESULTS: Here, we report that mice deficient in p35 display increased glucose uptake in the cerebral cortex, basal hyperactivity, and paradoxical decreased locomotion in response to chronic injection of cocaine or methylphenidate. Knockout mice also exhibited an increased susceptibility to changes in PFC neurotransmitter content after chronic methylphenidate exposure and altered basal DAergic activity in acute striatal and PFC slices. CONCLUSIONS: Our findings suggest that dysregulation of Cdk5/p35 activity during development may contribute to ADHD pathology, as indicated by the behavioral phenotype, improperly established mesolimbic circuitry, and aberrations in striatal and PFC catecholaminergic signaling in p35 knockout mice.
BACKGROUND:Attention-deficit/hyperactivity disorder (ADHD) may result from delayed establishment of corticolimbic circuitry or perturbed dopamine (DA) neurotransmission. Despite the widespread use of stimulants to treat ADHD, little is known regarding their long-term effects on neurotransmitter levels and metabolism. Cyclin-dependent kinase 5 (Cdk5) regulates DA signaling through control of synthesis, postsynaptic responses, and vesicle release. Mice lacking the Cdk5-activating cofactor p35 are deficient in cortical lamination, suggesting altered motor/reward circuitry. METHODS: We employed mice lacking p35 to study the effect of altered circuitry in vivo. Positron emission tomography measured glucose metabolism in the cerebral cortex using 2-deoxy-2-[¹⁸F] fluoro-d-glucose as the radiotracer. Retrograde dye tracing and tyrosine hydroxylase immunostains assessed the effect of p35 knockout on the medial prefrontal cortex (PFC), especially in relation to mesolimbic circuit formation. We defined the influence of Cdk5/p35 activity on catecholaminergic neurotransmission and motor activity via examination of locomotor responses to psychostimulants, monoamine neurotransmitter levels, and DA signal transduction. RESULTS: Here, we report that mice deficient in p35 display increased glucose uptake in the cerebral cortex, basal hyperactivity, and paradoxical decreased locomotion in response to chronic injection of cocaine or methylphenidate. Knockout mice also exhibited an increased susceptibility to changes in PFC neurotransmitter content after chronic methylphenidate exposure and altered basal DAergic activity in acute striatal and PFC slices. CONCLUSIONS: Our findings suggest that dysregulation of Cdk5/p35 activity during development may contribute to ADHD pathology, as indicated by the behavioral phenotype, improperly established mesolimbic circuitry, and aberrations in striatal and PFC catecholaminergic signaling in p35 knockout mice.
Authors: Susheel Vijayraghavan; Min Wang; Shari G Birnbaum; Graham V Williams; Amy F T Arnsten Journal: Nat Neurosci Date: 2007-02-04 Impact factor: 24.884
Authors: J A Bibb; J Chen; J R Taylor; P Svenningsson; A Nishi; G L Snyder; Z Yan; Z K Sagawa; C C Ouimet; A C Nairn; E J Nestler; P Greengard Journal: Nature Date: 2001-03-15 Impact factor: 49.962
Authors: J A Bibb; G L Snyder; A Nishi; Z Yan; L Meijer; A A Fienberg; L H Tsai; Y T Kwon; J A Girault; A J Czernik; R L Huganir; H C Hemmings; A C Nairn; P Greengard Journal: Nature Date: 1999-12-09 Impact factor: 49.962
Authors: A J Zametkin; L L Liebenauer; G A Fitzgerald; A C King; D V Minkunas; P Herscovitch; E M Yamada; R M Cohen Journal: Arch Gen Psychiatry Date: 1993-05
Authors: M Ernst; L L Liebenauer; A C King; G A Fitzgerald; R M Cohen; A J Zametkin Journal: J Am Acad Child Adolesc Psychiatry Date: 1994 Jul-Aug Impact factor: 8.829
Authors: June Bryan de la Peña; Irene Joy Dela Peña; Raly James Custodio; Chrislean Jun Botanas; Hee Jin Kim; Jae Hoon Cheong Journal: Mol Neurobiol Date: 2017-05-22 Impact factor: 5.590
Authors: Belén Goitia; Mariana Raineri; Laura E González; José L Rozas; Edgar Garcia-Rill; Verónica Bisagno; Francisco J Urbano Journal: J Neurochem Date: 2013-01-07 Impact factor: 5.372